澄实生物致力于利用人工智能与 mRNA 技术平台,开发针对肿瘤和传染病的创新疗法与疫苗,让更多患者获得前沿治疗。
TheraRNA leverages AI and mRNA technology platforms to develop innovative therapies and vaccines targeting cancer and infectious diseases.
了解核心技术 Explore our technology我们相信,人工智能与免疫学的深度融合将彻底改变药物研发的范式。从 AI 新生抗原预测到自研 LNP 递送系统,从 mRNA 分子设计到 GMP 规模化量产——澄实生物构建了全链条自主可控的技术闭环,打通从算法到产品的完整路径。
We believe the deep integration of artificial intelligence and immunology will fundamentally transform drug development. From AI neoantigen prediction to proprietary LNP delivery systems, from mRNA molecular design to GMP mass production — TheraRNA has built a fully self-controlled technology closed loop, bridging algorithm to product.
了解更多 Read more
基于 AI 新生抗原预测的个性化肿瘤 mRNA 疫苗,联合多家三甲医院开展 IIT 临床研究,客观缓解率达 67%。
Individualized mRNA cancer vaccines based on AI neoantigen prediction, with IIT clinical studies at top hospitals achieving 67% ORR.
了解管线Learn more全球首创耐药细菌 mRNA 疫苗管线,金黄色葡萄球菌 mRNA 疫苗已完成多轮动物实验验证,攻克免疫印记难题。
World's first anti-drug-resistant bacteria mRNA vaccine pipeline. S. aureus vaccine validated in multiple animal studies, overcoming immune imprinting.
了解管线Learn more动保反哺人用,以定制化 mRNA 动物疫苗快速验证技术路径,覆盖猫狗绝育、弓形虫、宠物肿瘤等蓝海品种。
Veterinary products validating human therapeutics. Customized mRNA animal vaccines covering sterilization, toxoplasmosis, and pet oncology.
了解管线Learn more利用 mRNA 技术平台的强大通用性和 AI 算法的高效迭代能力,构建覆盖多适应症的丰富管线。
Leveraging the versatility of mRNA platforms and AI-driven rapid iteration to build a diversified pipeline across multiple indications.